Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
This case presentation describes the novel use of combined PDE3 and PDE5 inhibitors in end-stage heart failure, a combination not previously reported.
Heart failure (HF) is the leading cause of morbidity and mortality and is evolving to epidemic proportions. Despite pharmacologic advances and device interventions, HF remains a progressive disease. The phosphodiesterase inhibitors-3 (PDE3I), and more recently, the phosphodiesterase inhibitors-5 (PDE5I) have been used as part of the treatment in certain patients, however, such combination has not been studied or reported before.
No takes yet. Share an insight, caveat, or question.
Reyna et al. (2013) conducted a case report in End-stage heart failure (n=1). Tadalafil added to milrinone was evaluated on Clinical and functional improvement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: